Back

The comparison of short-term dual antiplatelet therapy versus standard dual antiplatelet therapy in elderly patients with coronary artery disease who underwent percutaneous coronary intervention

2 September 2024 (11:00 - 11:50)
Organised by: Logo
Congress Presentation Part of: Data-driven decisions for anticoagulant and antiplatelet therapy Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor In Tae Jin

Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul (Korea (Republic of))

7 More presentations in this session

Presentation thumbnail
Comparative discontinuation and non-bleeding side effects of Clopidogrel, Prasugrel and Ticagrelor in patients with acute coronary syndromes; a Network Meta-analysis of Randomized Controlled Trials
Doctor S. Yanko (Jerusalem, IL)
Abstract Slides Video
Presentation thumbnail
Anticoagulant monotherapy versus anticoagulant therapy in combination with single antiplatelet agent in patients after coronary artery bypass grafting - analysis of real-world data
Associate Professor R. Dabrowski (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Impact of procedural and patient-related risks on 1-year outcomes for patients with 1-month DAPT followed by P2Y12 inhibitor monotherapy after biodegradable-polymer drug-eluting stent implantation
Doctor R. Shimada (Yahaba, JP)
Abstract Slides Video
Presentation thumbnail
Clinical outcomes of risk score-guided dual antiplatelet therapy in patients with acute coronary syndrome who underwent percutaneous coronary intervention
Assistant Professor D. Hyun (Kwang Ju, KR)
Abstract Slides Video
Presentation thumbnail
Elderly patients are hyperresponsive to potent P2Y12 inhibitors
Doctor D. Mutschlechner (Mistelbach, AT)
Abstract Slides Video

Access the full session

Session thumbnail
Data-driven decisions for anticoagulant and antiplatelet therapy

The Event

Event poster

ESC Congress 2024

2 September 2024 11:00 CET
You may be interested in
thumbnail
Congress Presentation
A shorter duration of dual-antiplatelet therapy following percutaneous coronary intervention: a meta-analysis of randomized clinical trials
thumbnail
Congress Presentation
Following an acute coronary syndrome, the default duration of dual antiplatelet therapy should be 12 months: pro
thumbnail
Congress Presentation
Should 12 months of dual antiplatelet therapy still be the default recommendation after primary PCI?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources